Ep38: Harlan and Chad Robins (Take 2)

Episode Summary

Executive Summary: Adaptive Biotechnologies’ founders Harlan and Chad Robbins explain how sequencing T and B cell receptors turned the adaptive immune system into a platform for diagnostics and therapeutics. The company evolved from academic research to FDA-cleared ClonoSeq MRD testing, a Microsoft partnership for antigen mapping, and a $300M-upfront Genentech collaboration to build TCR-based cell therapies.

Main Topics: Origins of Adaptive and the Robbins brothers’ backgrounds (Priority: 4/5): The episode opens with the founders’ upbringing, career paths, and complementary personalities: Harlan as the science-driven academic physicist-turned-biologist, Chad as the business-focused operator from banking and investing. The scientific foundation: sequencing adaptive immune receptors (Priority: 5/5): Harlan explains how T- and B-cell receptors are created through gene rearrangement, producing a highly diverse immune repertoire that can be read by next-generation sequencing to reveal disease-relevant information. From academic curiosity to a commercial company (Priority: 5/5): The company emerged when Harlan’s Fred Hutch research generated unusually large amounts of data and external demand from other researchers, prompting the brothers to form Adaptive and monetize the technology through research services. ClonoSeq and minimal residual disease diagnostics (Priority: 5/5): Adaptive’s first major clinical product tracks cancer-specific receptor sequences to detect minimal residual disease with much greater sensitivity than flow cytometry, enabling prognosis, relapse monitoring, and treatment decisions. Platform expansion into pharma, Microsoft, and Genentech (Priority: 5/5): The discussion covers how Adaptive moved into pharma partnerships, a Microsoft collaboration to map antigens to receptors using cloud/ML, and a Genentech deal to develop both off-the-shelf and personalized TCR-based cancer therapies. Business strategy, prioritization, and keeping the platform together (Priority: 4/5): Chad explains why Adaptive remains a single integrated company: shared infrastructure, cross-application learning, and a platform mindset spanning research, diagnostics, and therapeutics rather than separate spinouts. Long-term vision: immune-system-based medicine (Priority: 5/5): Both founders frame Adaptive’s mission as reading the immune system as the body’s best diagnostic and therapeutic layer, with future applications in cancer, autoimmunity, infectious disease, and serial monitoring.

Key Arguments: The adaptive immune system contains dynamic, sequence-encoded information that can be measured and translated into diagnostics and therapies. Sequencing T- and B-cell receptors provides a deeper, more quantitative, and more standardized view than older cell-counting methods like flow cytometry. Cancer cells often carry a unique rearranged receptor sequence that functions like a barcode, enabling highly sensitive minimal residual disease detection. The company’s original business plan already envisioned both diagnostics and therapeutics; later market and scientific developments merely validated that direction. A platform model works because the same receptor-mapping infrastructure supports research, diagnostics, and TCR-based drug discovery. Genentech’s partnership extends Adaptive from discovery into therapeutic manufacturing, while Microsoft accelerates large-scale antigen-receptor mapping with machine learning and cloud computing. Adaptive believes the immune system can serve as a universal diagnostic layer because it reflects current and prior disease states, not just inherited risk. Keeping the company unified preserves shared scientific, computational, and operational capabilities that would be harder to replicate in separate businesses.

Data Points: Company valuation status: Unicorn (private company valued at more than $1 billion) - Luke introduces Adaptive as one of biotech’s unicorns Initial friends-and-family financing: $4-5 million - Chad describes the first capital raised in 2009 Genentech upfront payment: $300 million - Luke references the upfront amount in the Genentech partnership FDA-approved ClonoSeq indications: 2 - Multiple myeloma and acute lymphoblastic leukemia are named as the first approved uses Sequencing sensitivity vs flow cytometry: 1 cell in 1,000,000 vs 1 cell in 10,000 - Harlan and Chad compare Adaptive’s method to flow cytometry for MRD detection Research output at scale: More data in one day than the field had generated in 30 years - Harlan describes early sequencing runs at Fred Hutch Clinical validation papers: About 50 papers - Chad says the company accumulated extensive evidence before FDA/payer conversations Founding year: 2009 - The brothers launch Adaptive after Harlan’s research demand outgrew the academic setting Fred Hutch arrival: 2006 - Harlan moved from Princeton to Fred Hutchinson Cancer Research Center Microsoft collaboration duration mentioned: 1 year - Chad says the partnership had been underway for about a year

Pivotal Quotes: "We’re an immune-driven medicine company now." — Chad Robbins: Summarizing Adaptive’s evolution from research tools into diagnostics and therapeutics "The ultimate goal is a universal blood-based diagnostic." — Luke Timmerman: Describing the Microsoft/Adaptive antigen-mapping vision and why the collaboration matters "Our goal is to do the immune system better than anyone out there." — Chad Robbins: Explaining why the company keeps research, diagnostics, and therapeutics under one platform

Implications: Adaptive’s model suggests immune profiling could become a core clinical layer for early disease detection, MRD monitoring, and personalized cell therapy. If validated broadly, the immune system may become a routine readout akin to imaging or genomics.